NuCana's NUC-7738 enhances carfilzomib activity in preclinical multiple myeloma study
NCNA•NuCana said preclinical findings showed NUC-7738 enhanced carfilzomib's anti-cancer activity in multiple myeloma cell lines. Final Phase 2 results for NUC-7738 with pembrolizumab in PD-1 inhibitor-resistant metastatic melanoma are scheduled for presentation Dec. 14-16, 2026, in London.




